Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild…
Modern Dental Group Announces 2026 Interim Results
Merdeka Gold Delivers Strong Q2 Production Ramp-Up as Pani Gold Mine Advances Toward Full-year Growth
Nissin Foods Announces 2026 Interim Results
The World’s Leading Minds in Biotechnology Will Meet in Riyadh This September
Overseas Growth Gathers Momentum as CanSinoBIO’s Global Strategy Unlocks New Opportunities